《大行报告》摩通下调华润医药(03320.HK)目标价至4.5元 评级「中性」
摩根大通发表报告指,华润医药(03320.HK)最近公布计划斥53.58亿元人民币收购博雅生物制药(300294.SZ)控股权,认为是次收购可使集团渗透至增长快、盈利能力强劲及入场门槛高的血液产品行业。而集团股价在交易公布後的反应亦正面,上升了约8%,对比MSCI中国医疗健康指数为升约3%。
该行表示,虽然认为华润医药的举动正面,但相信来自集中采购的持续挑战、疫情造成的破坏扩大,及东阿阿胶(000423.SZ)渠道去库存继续,会限制集团股份的上升。
摩通下调华润医药股股份目标价,由5元降至4.5元,评级维持「中性」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.